SCHEMBL7679901

SCHEMBL7679901

O=C(NN=Cc1ccc([N+](=O)[O-])cc1)c1[nH]c2ccccc2c1-c1ccc(F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.57
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
LMNA P02545 5/20 0.57
RAB9A P51151 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
POLB P06746 2/20 0.57
GAA P10253 1/20 0.57
NPC1 O15118 3/20 0.56
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55
MAPK1 P28482 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
MITF O75030 1/20 0.52
PKM P14618 1/20 0.52
HTT P42858 1/20 0.52
PAX8 Q06710 1/20 0.51
TUBB4A P04350 2/20 0.50
TUBB P07437 2/20 0.50
TUBA3C P0DPH7 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7679897 1.00 MAPT (0.57) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL7678017 0.90 MAPT (0.57) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL7678021 0.90 MAPT (0.57) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL7561118 0.89 MAPT (0.65) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL7561111 0.89 MAPT (0.65) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL7560802 0.86 MAPT (0.66) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL7562483 0.86 TUBB4A (0.63) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL7562479 0.86 TUBB4A (0.63) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL7560806 0.86 MAPT (0.66) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL7672512 0.86 MEN1 (0.61) MAPTMEN1KMT2ALMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885MEN1 3165/4885KMT2A 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.